GDC-0084 is primarily utilized in the field of oncology, specifically targeting the PI3K/mTOR pathway, which is often dysregulated in various cancers. It is being investigated as a potential therapeutic agent for treating glioblastoma, a highly aggressive form of brain cancer. By inhibiting this pathway, GDC-0084 aims to disrupt the growth and survival of cancer cells, potentially slowing tumor progression. Its ability to cross the blood-brain barrier makes it particularly promising for addressing central nervous system malignancies. Clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosing in patients with advanced solid tumors, particularly those with PI3K pathway alterations.